colorectal {frailtypack}

Follow-up of metastatic colorectal cancer patients: times of new lesions appearance and death

Description

Randomly chosen 150 patients from the follow-up of the FFCD 2000-05 multicenter phase III clinical trial originally including 410 patients with metastatic colorectal cancer randomized into two therapeutic strategies: combination and sequential. The dataset contains times of observed appearances of new lesions censored by a terminal event (death or right-censoring) with baseline characteristics (treatment arm, age, WHO performance status and previous resection).

Usage

data(colorectal)

Format

This data frame contains the following columns:

id

identification of each subject. Repeated for each recurrence

time0

start of interval (0 or previous recurrence time)

time1

recurrence or censoring time

new.lesions

Appearance of new lesions status. 0: censsored or no event, 1: new lesions

treatment

To which treatment arm a patient was allocated? 1: sequential (S); 2: combination (C)

age

Age at baseline: 1: <50 years, 2: 50-69 years, 3: >69 years

who.PS

WHO performance status at baseline: 1: status 0, 2: status 1, 3: status 2

prev.resection

Previous resection of the primate tumor? 0: No, 1: Yes

state

death indicator. 0: alive, 1: dead

gap.time

interocurrence time or censoring time

Note

We thank the Federation Francophone de Cancerologie Digestive and Gustave Roussy for sharing the data of the FFCD 2000-05 trial supported by an unrestricted Grant from Sanofi.

References

M. Ducreux, D. Malka, J. Mendiboure, P.-L. Etienne, P. Texereau, D. Auby, P. Rougier, M. Gasmi, M. Castaing, M. Abbas, P. Michel, D. Gargot, A. Azzedine, C. Lombard- Bohas, P. Geoffroy, B. Denis, J.-P., Pignon, L.,Bedenne, and O. Bouche (2011). Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. The Lancet Oncology 12, 1032-44.